{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:32:29Z","timestamp":1773297149723,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["2021.06125"],"award-info":[{"award-number":["2021.06125"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["54499\/2020 .04442"],"award-info":[{"award-number":["54499\/2020 .04442"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["54499\/2021 .06125"],"award-info":[{"award-number":["54499\/2021 .06125"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["2020.04442"],"award-info":[{"award-number":["2020.04442"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bcp.2024.116616","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T10:00:15Z","timestamp":1731146415000},"page":"116616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P3","title":["Unveiling the potential of intranasal delivery of renin-angiotensin system drugs: Insights on the pharmacokinetics of irbesartan"],"prefix":"10.1016","volume":"230","author":[{"given":"Filipa","family":"Gouveia","sequence":"first","affiliation":[]},{"given":"Andreia","family":"Carona","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Lacerda","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"given":"Antoni","family":"Camins","sequence":"additional","affiliation":[]},{"given":"M.","family":"Teresa Cruz","sequence":"additional","affiliation":[]},{"given":"Miren","family":"Ettcheto","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116616_b0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects","volume":"38","author":"Marino","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116616_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0206705","article-title":"The association of multiple anti-hypertensive medication classes with Alzheimer \u2019 s disease incidence across sex, race, and ethnicity","volume":"13","author":"Barthold","year":"2018","journal-title":"PLoS One."},{"key":"10.1016\/j.bcp.2024.116616_b0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JAD-2011-110347","article-title":"Associations of Anti-Hypertensive Treatments with Alzheimer \u2019 s Disease, Vascular Dementia, and Other Dementias","volume":"26","author":"Davies","year":"2014","journal-title":"J. Alzheimar\u2019s Dis."},{"key":"10.1016\/j.bcp.2024.116616_b0020","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/jgs.13627","article-title":"Renin-Angiotensin-System Modulation may slow the Conversion from Mild Cognitive Impairment to Alzheimer \u2019 s Disease","volume":"63","author":"Wharton","year":"2015","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.bcp.2024.116616_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111471","article-title":"Intranasal irbesartan reverts cognitive decline and activates the PI3K\/AKT pathway in an LPS-induced neuroinflammation mice model","volume":"128","author":"Gouveia","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2024.116616_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101612","article-title":"Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer\u2019s disease: Past, present and future","volume":"77","author":"Gouveia","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bcp.2024.116616_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0014-2999(98)00329-X","article-title":"Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment","volume":"352","author":"Polidori","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116616_b0040","first-page":"203","article-title":"Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics","volume":"5","author":"Kumar","year":"2017","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.bcp.2024.116616_b0045","first-page":"2088","article-title":"Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting","volume":"46","author":"Selvaraj","year":"2018","journal-title":"Artif. Cells, Nanomedicine Biotechnol."},{"key":"10.1016\/j.bcp.2024.116616_b0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ner.12399","article-title":"Trigeminal Nerve Stimulation for Comorbid Posttraumatic Stress Disorder and Major Depressive Disorder","volume":"19","author":"Cook","year":"2016","journal-title":"Neuromodulation."},{"key":"10.1016\/j.bcp.2024.116616_b0055","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2024.116616_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213663","article-title":"Combining donepezil and memantine via mannosylated PLGA nanoparticles for intranasal delivery: Characterization and preclinical studies","volume":"154","author":"Handa","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.bcp.2024.116616_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117540","article-title":"Insulin mediated novel therapies for the treatment of Alzheimer\u2019s disease","volume":"249","author":"Dubey","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2024.116616_b0070","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/sj.jhh.1000991","article-title":"Clinical pharmacokinetics of angiotensin II (AT 1) receptor blockers in hypertension","volume":"14","author":"Israili","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.bcp.2024.116616_b0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/HYPERTENSIONAHA.121.17049","article-title":"Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis","volume":"78","author":"Ho","year":"2021","journal-title":"Hypertension."},{"key":"10.1016\/j.bcp.2024.116616_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.751321","article-title":"Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration. In Vitro\/In Vivo Evaluation","volume":"12","author":"Silva","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116616_b0085","unstructured":"in B.E. of M.D. ISO 10993-5:2009(E), Part 5: Test for In Vitro Citotoxicity, ISO (2009), Geneva, Switz. Int. Organ. Stand. 34 (2009)."},{"key":"10.1016\/j.bcp.2024.116616_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1528-1167.2012.03409.x","article-title":"Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique","volume":"53","author":"Fortuna","year":"2012","journal-title":"Epilepsia."},{"key":"10.1016\/j.bcp.2024.116616_b0095","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/sj.bjp.0704668","article-title":"Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-\/-) mice","volume":"135","author":"Stephens","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116616_b0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2005.11.011","article-title":"Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine","volume":"111","author":"Werle","year":"2006","journal-title":"J. Control. Release."},{"key":"10.1016\/j.bcp.2024.116616_b0105","article-title":"Supramolecular ternary inclusion complexes of Irbesartan with hydroxypropyl-beta-cyclodextrin","volume":"67","author":"Suvarna","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bcp.2024.116616_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.04.047","article-title":"Nose-to-brain delivery of levetiracetam after intranasal administration to mice","volume":"564","author":"Gon\u00e7alves","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2024.116616_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123145","article-title":"Nose-to-brain delivery of perampanel formulated in a self-microemulsifying drug delivery system improves anticonvulsant and anxiolytic activity in mice","volume":"642","author":"Meirinho","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2024.116616_b0120","first-page":"3","article-title":"Olfactory assays for mouse models of neurodegenerative disease","author":"Lehmkuhl","year":"2014","journal-title":"J. vis. Exp."},{"key":"10.1016\/j.bcp.2024.116616_b0125","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jssc.200700442","article-title":"Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method","volume":"31","author":"Ferreir\u00f3s","year":"2008","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.bcp.2024.116616_b0130","first-page":"2","article-title":"ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis","volume":"44","author":"European Medicines Agency","year":"2022","journal-title":"EMA Sci. Med. Heal."},{"key":"10.1016\/j.bcp.2024.116616_b0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0928-0987(98)00023-2","article-title":"Nasal drug delivery - Evaluation of an in vitro model using porcine nasal mucosa","volume":"7","author":"Wadell","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116616_b0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejpb.2009.08.008","article-title":"RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies","volume":"74","author":"Wengst","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bcp.2024.116616_b0145","first-page":"1","article-title":"A549 as an In Vitro Model to Evaluate the Impact of Microplastics in the Air","volume":"12","author":"Shahzadi","year":"2023","journal-title":"Biology (basel)."},{"key":"10.1016\/j.bcp.2024.116616_b0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/excr.1998.4172","article-title":"Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism","volume":"243","author":"Foster","year":"1998","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2024.116616_b0155","first-page":"194","article-title":"Evaluation of the human cell line RPMI 2650 as an in vitro nasal model","volume":"33","author":"De Fraissinette","year":"1995","journal-title":"Rhinology."},{"key":"10.1016\/j.bcp.2024.116616_b0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11095-014-1494-0","article-title":"The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model","volume":"32","author":"Kreft","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2024.116616_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnins.2016.00598","article-title":"Resveratrol attenuates formaldehyde induced hyperphosphorylation of tau protein and cytotoxicity in N2a cells","volume":"10","author":"He","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2024.116616_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.hal.2021.101994","article-title":"Improving in vitro ciguatoxin and brevetoxin detection: selecting neuroblastoma (Neuro-2a) cells with lower sensitivity to ouabain and veratridine (OV-LS)","volume":"103","author":"Loeffler","year":"2021","journal-title":"Harmful Algae."},{"key":"10.1016\/j.bcp.2024.116616_b0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0928-0987(02)00240-3","article-title":"Permeability of porcine nasal mucosa correlated with human nasal absorption","volume":"18","author":"Wadell","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116616_b0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejpb.2020.04.011","article-title":"QbD-driven development of intranasal lipid nanoparticles for depression treatment","volume":"153","author":"Vitorino","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bcp.2024.116616_b0185","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40005-023-00630-1","article-title":"Amorphous nasal powder advanced performance: in vitro\/ex vivo studies and correlation with in vivo pharmacokinetics","volume":"53","author":"Henriques","year":"2023","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.bcp.2024.116616_b0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40005-012-0020-9","article-title":"Application of biopharmaceutics classification system (BCS) in drug transport studies across human respiratory epithelial cell monolayers","volume":"42","author":"Cho","year":"2012","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.bcp.2024.116616_b0195","unstructured":"Irbesartan- DrugBank, (n.d.)."},{"key":"10.1016\/j.bcp.2024.116616_b0200","doi-asserted-by":"crossref","unstructured":"A. Pires, A. Fortuna, G. Alves, A. Falc\u00e3o, Intranasal drug delivery: How, why and what for?, J. Pharm. Pharm. Sci. 12 (2009) 288\u2013311. 10.18433\/j3nc79.","DOI":"10.18433\/J3NC79"},{"key":"10.1016\/j.bcp.2024.116616_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105632","article-title":"Is intranasal administration an opportunity for direct brain delivery of lacosamide?","volume":"157","author":"Gon\u00e7alves","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116616_b0210","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-020-02786-z","article-title":"Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration","volume":"37","author":"Gon\u00e7alves","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2024.116616_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120161","article-title":"A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration","volume":"593","author":"Gon\u00e7alves","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2024.116616_b0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release."},{"key":"10.1016\/j.bcp.2024.116616_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105498","article-title":"Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks","volume":"153","author":"Karatza","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2024.116616_b0230","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/00912700122010645","article-title":"The pharmacokinetics of irbesartan in hypertensive children and adolescents","volume":"41","author":"Sakarcan","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116616_b0235","first-page":"311","article-title":"The New Angiotensin II Receptor Antagonist","author":"Brunner","year":"1997","journal-title":"Irbesartan"},{"key":"10.1016\/j.bcp.2024.116616_b0240","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/pch\/16.9.535","article-title":"Pharmacokinetics 101","volume":"16","author":"Ito","year":"2011","journal-title":"Paediatr. Child Health (oxford)"},{"key":"10.1016\/j.bcp.2024.116616_b0245","first-page":"59","article-title":"Protective Effect of Irbesartan an Angiotensin (AT1) Receptor Antagonist in Unpredictable Chronic Mild Stress Induced Depression in Mice","volume":"67","author":"Ayyub","year":"2017","journal-title":"Drug Res. (stuttg)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T01:01:41Z","timestamp":1732928501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224006166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"alternative-id":["S0006295224006166"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116616","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the potential of intranasal delivery of renin-angiotensin system drugs: Insights on the pharmacokinetics of irbesartan","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116616"}}